Synonyms: CCX282-B | GSK'786 | GSK1605786 | GSK1605786A | Traficet-EN
Compound class:
Synthetic organic
Comment: Vercirnon (CCX282-B) is a selective, potent and orally bioavailable antagonist of the chemokine (C-C motif) receptor 9 (CCR9 chemokine receptor) [1]. It was developed for potential to treat inflammatory bowel disease.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Three out of four Phase 3 clinical trials evaluating vercirnon (using research code GSK1605786A) in Crohn's disease were terminated due to lack of efficacy. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
CCR9-mediated CCL25-directed chemotaxis is known to be required for migration of immune cells into the intestine. CCR9 antagonist-induced blockade of T cell migration to the gut is hypothesised to reduce inflammation in inflammatory bowel conditions [1]. |